Enanta Pharmaceuticals Inc (ENTA) stock
ENTANasdaqPharmaceutical PreparationsFiscal year ends September 30
Financials through Q4 FY2026, quarter ended Sep 30, 2026Last filing: 10-K on Nov 18, 2026Score 2/302% above fair value
$8.69−1.98 (-18.56%)
Close on Nov 17, 2026Market cap $253.10MP/E –Yield –
Enanta Pharmaceuticals price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
Enanta Pharmaceuticals's price to sales ratio was 5.2× on Nov 11, 2026, against 4.6× a year earlier. Over the last 5 years it ranged from 1.6× to 15.7×, with a median of 5.0×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 5.2× | +0.0 |
| 2025 | Dec 31, 2025 | 5.2× | +3.3 |
| 2024 | Dec 31, 2024 | 1.8× | −0.7 |
| 2023 | Dec 29, 2023 | 2.5× | −8.7 |
| 2022 | Dec 30, 2022 | 11.2× | −4.4 |
| 2021 | Dec 31, 2021 | 15.6× | +8.7 |
| 2020 | Dec 31, 2020 | 6.9× | +1.0 |
| 2019 | Dec 31, 2019 | 5.9× | −0.7 |
| 2018 | Dec 31, 2018 | 6.6× | −4.3 |
| 2017 | Dec 29, 2017 | 10.9× | +3.7 |
| 2016 | Dec 30, 2016 | 7.2× | +3.4 |
| 2015 | Dec 31, 2015 | 3.8× | −16.0 |
| 2014 | Dec 31, 2014 | 19.8× | +4.5 |
| 2013 | Dec 31, 2013 | 15.3× | – |
See a number that looks wrong?